WO2004081043A3 - Variants de baff et leurs methodes d'utilisation - Google Patents

Variants de baff et leurs methodes d'utilisation Download PDF

Info

Publication number
WO2004081043A3
WO2004081043A3 PCT/US2004/006779 US2004006779W WO2004081043A3 WO 2004081043 A3 WO2004081043 A3 WO 2004081043A3 US 2004006779 W US2004006779 W US 2004006779W WO 2004081043 A3 WO2004081043 A3 WO 2004081043A3
Authority
WO
WIPO (PCT)
Prior art keywords
baff
amino acid
acid substitution
mutants
production
Prior art date
Application number
PCT/US2004/006779
Other languages
English (en)
Other versions
WO2004081043A2 (fr
Inventor
John R Desjarlais
Eugene Zhukovsky
Adam Read Thomason
Original Assignee
Xencor Inc
John R Desjarlais
Eugene Zhukovsky
Adam Read Thomason
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/338,083 external-priority patent/US20030166559A1/en
Application filed by Xencor Inc, John R Desjarlais, Eugene Zhukovsky, Adam Read Thomason filed Critical Xencor Inc
Priority to EP04718010A priority Critical patent/EP1606312A2/fr
Priority to AU2004220078A priority patent/AU2004220078A1/en
Priority to CA002523776A priority patent/CA2523776A1/fr
Publication of WO2004081043A2 publication Critical patent/WO2004081043A2/fr
Publication of WO2004081043A3 publication Critical patent/WO2004081043A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne de nouvelles protéines présentant un antagoniste négatif dominant de BAFF, une activité agoniste et une activité antagoniste de récepteur, et des acides nucléiques codant ces protéines. L'invention concerne également l'utilisation de nouvelles protéines dans le traitement de troubles associés à BAFF ou à APRIL.
PCT/US2004/006779 2003-01-06 2004-03-05 Variants de baff et leurs methodes d'utilisation WO2004081043A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP04718010A EP1606312A2 (fr) 2003-03-07 2004-03-05 Mutants de baff portant au moins une substitution d'un acide amine et leurs methodes de production
AU2004220078A AU2004220078A1 (en) 2003-03-07 2004-03-05 BAFF mutants with at least one amino acid substitution and methods of their production
CA002523776A CA2523776A1 (fr) 2003-03-07 2004-03-05 Variants de baff et leurs methodes d'utilisation

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10/338,083 US20030166559A1 (en) 2002-01-04 2003-01-06 Dominant negative proteins and methods thereof
US45270703P 2003-03-07 2003-03-07
US60/452,707 2003-03-07
US52388003P 2003-11-20 2003-11-20
US60/523,880 2003-11-20
US52810403P 2003-12-08 2003-12-08
US60/528,104 2003-12-08

Publications (2)

Publication Number Publication Date
WO2004081043A2 WO2004081043A2 (fr) 2004-09-23
WO2004081043A3 true WO2004081043A3 (fr) 2004-12-29

Family

ID=35351878

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/006779 WO2004081043A2 (fr) 2003-01-06 2004-03-05 Variants de baff et leurs methodes d'utilisation

Country Status (4)

Country Link
EP (1) EP1606312A2 (fr)
AU (1) AU2004220078A1 (fr)
CA (1) CA2523776A1 (fr)
WO (1) WO2004081043A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057856A2 (fr) 2002-01-04 2003-07-17 Xencor Proteines negatives dominantes et procedes associes
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
US20050130892A1 (en) * 2003-03-07 2005-06-16 Xencor, Inc. BAFF variants and methods thereof
WO2005113598A2 (fr) * 2004-05-21 2005-12-01 Xencor, Inc. Membres de la superfamille des tnf avec immunogenicite modifiee
EP1814577B1 (fr) 2004-10-13 2014-04-23 The Washington University Utilisation de baff dans le traitement du sepsis
NZ597082A (en) 2005-10-13 2013-11-29 Human Genome Sciences Inc Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases
CA2629306A1 (fr) 2005-11-23 2007-05-31 Genentech, Inc. Procedes et compositions lies a des analyses de lymphocytes b
WO2013171296A1 (fr) 2012-05-16 2013-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Diagnostic et traitement de la sarcoïdose
CZ2012561A3 (cs) * 2012-08-22 2013-10-23 Masarykova Univerzita B-bunecný aktivující faktor pro zvýsení sliznicní imunity kojencu a prípravek jej obsahující
US10126301B2 (en) 2013-02-08 2018-11-13 Institute For Myeloma & Bone Cancer Research Diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and B-cell non-hodgkin lymphoma
US9688767B2 (en) 2013-03-15 2017-06-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method of predicting survival time in myocardial infarction patients by measuring BAFF levels
CA3010019A1 (fr) 2016-01-12 2017-07-20 James Richard BERENSON Methodes ameliorees pour surveiller l'etat immunitaire d'un sujet
WO2017201040A1 (fr) * 2016-05-16 2017-11-23 Berenson James Richard Méthodes améliorées pour surveiller l'état immunitaire d'un sujet
US11635435B2 (en) 2017-06-13 2023-04-25 Oncotracker, Inc. Diagnostic, prognostic, and monitoring methods for solid tumor cancers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043032A2 (fr) * 1999-01-25 2000-07-27 Biogen, Inc. Baff, agents bloquants associes et utilisation de ceux-ci pour stimuler et inhiber la reponse immunitaire des lymphocytes b et des immunoglobulines
WO2002018620A2 (fr) * 2000-08-15 2002-03-07 Human Genome Sciences, Inc. Neutrokine-alpha et variant d'epissage de neutrokine-alpha

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043032A2 (fr) * 1999-01-25 2000-07-27 Biogen, Inc. Baff, agents bloquants associes et utilisation de ceux-ci pour stimuler et inhiber la reponse immunitaire des lymphocytes b et des immunoglobulines
WO2002018620A2 (fr) * 2000-08-15 2002-03-07 Human Genome Sciences, Inc. Neutrokine-alpha et variant d'epissage de neutrokine-alpha

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS, XP002289894, Retrieved from the Internet <URL:http://www.xencor.com/news/releases/1282004-91.html> [retrieved on 20040721] *
KAWASAKI A ET AL: "Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis.", GENES AND IMMUNITY, vol. 3, no. 7, November 2002 (2002-11-01), pages 424 - 429, XP009034180, ISSN: 1466-4879 *
KIM HO MIN ET AL: "Crystal structure of the BAFF-BAFF-R complex and its implications for receptor activation.", NATURE STRUCTURAL BIOLOGY, vol. 10, no. 5, May 2003 (2003-05-01), pages 342 - 348, XP002289896, ISSN: 1072-8368 *
LIU YINGFANG ET AL: "Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 108, no. 3, 8 February 2002 (2002-02-08), pages 383 - 394, XP002286032, ISSN: 0092-8674 *

Also Published As

Publication number Publication date
CA2523776A1 (fr) 2004-09-23
AU2004220078A1 (en) 2004-09-23
EP1606312A2 (fr) 2005-12-21
WO2004081043A2 (fr) 2004-09-23

Similar Documents

Publication Publication Date Title
WO2004081043A3 (fr) Variants de baff et leurs methodes d&#39;utilisation
WO2005063820A3 (fr) Proteines de fusion de il-7
WO2001064889A3 (fr) CONCEPTION ET DECOUVERTE DE VARIANTS DU TNF-α A BASE DE PROTEINES DESTINES AU TRAITEMENT DES PATHOLOGIES LIEES AU TNF-$g(a)
WO2006034106A3 (fr) Variantes baff et procedes associes
WO2004018633A3 (fr) Acides nucleiques et proteines abca13 : utilisations
EP2083018A3 (fr) Compositions et procédés associés à STOP-1
WO2003016551A3 (fr) Proteine de liaison a l&#39;acide salicylique codant des acides nucleiques, proteine de liaison a l&#39;acide salicylique 2 (sabp2) et methodes d&#39;utilisation associees
WO2000068364A3 (fr) Mutations de molecules d&#39;acide nucleique codant pour la dehydrogenase de retinol 11-cis, proteines mutantes et utilisations
PL374550A1 (en) Il-17 like molecules and uses thereof
WO2005035564A3 (fr) Variants de tnf-alpha a base proteique destines au traitement de troubles associes au tnf-alpha
WO2004089982A3 (fr) Variantes april et leurs procedes
WO2004003133A3 (fr) Molecules signalisant la douleur
AU2003241361A1 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
AU2003210945A8 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
AU2003251293A8 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2004018702A3 (fr) Acides nucleiques et proteines nphp
AU2003217864A1 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
AU2003213721A1 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
AU2003235476A1 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
AU2003222241A8 (en) Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
AU2003213720A8 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2002059310A3 (fr) Polynucleotides encoding cellular transporters and methods of use thereof
AU2003215179A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and used thereof
AU2003215212A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2003076644A9 (fr) Proteines transporteurs humaines isolees, molecules d&#39;acide nucleique codant des proteines transporteurs humaines et leurs utilisations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004220078

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004718010

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2523776

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2004718010

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004220078

Country of ref document: AU

Date of ref document: 20040305

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004220078

Country of ref document: AU

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)